Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges
Noncoding RNAs (ncRNAs) defy the central dogma by representing a family of RNA molecules that are not translated into protein but can convey information encoded in their DNA. Elucidating the exact function of ncRNA has been a focus of discovery in the last decade and remains challenging. Nevertheles...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/2/276 |
| _version_ | 1827652354247229440 |
|---|---|
| author | Victor E. Nava Pin-Yu Perera Nirbhay Kumar Maneesh Jain |
| author_facet | Victor E. Nava Pin-Yu Perera Nirbhay Kumar Maneesh Jain |
| author_sort | Victor E. Nava |
| collection | DOAJ |
| description | Noncoding RNAs (ncRNAs) defy the central dogma by representing a family of RNA molecules that are not translated into protein but can convey information encoded in their DNA. Elucidating the exact function of ncRNA has been a focus of discovery in the last decade and remains challenging. Nevertheless, the importance of understanding ncRNA is apparent since these molecules regulate gene expression at the transcriptional and post-transcriptional level exerting pleiotropic effects critical in development, oncogenesis, and immunity. NcRNAs have been referred to as “the dark matter of the nucleus”, and unraveling their role in physiologic and pathologic processes will provide vast opportunities for basic and translational research with the potential for significant therapeutic progress. Consequently, strong efforts are underway to exploit the therapeutic utility of ncRNA, some of which have been approved by the US Food and Drug Administration and the European Medicines Agency. The use of ncRNA therapeutics (or “vaccines” if defined as anti-disease agents) may result in improved curative strategies when used alone or in combination with existing treatments. This review will focus on the role of ncRNA therapeutics in prostatic carcinoma while exploring basic biological aspects of these molecules that represent about 97% of the transcriptome in humans. |
| first_indexed | 2024-03-09T20:53:20Z |
| format | Article |
| id | doaj.art-37e5ef2d9d55428f9002ac02de5a8a56 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T20:53:20Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-37e5ef2d9d55428f9002ac02de5a8a562023-11-23T22:26:25ZengMDPI AGVaccines2076-393X2022-02-0110227610.3390/vaccines10020276Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and ChallengesVictor E. Nava0Pin-Yu Perera1Nirbhay Kumar2Maneesh Jain3Pathology Service, Veterans Affair Medical Center, Washington, DC 20422, USAPathology Service, Veterans Affair Medical Center, Washington, DC 20422, USADepartment of Global Health, Milken Institute School of Public Health, The George Washington University, Washington, DC 20052, USADepartment of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USANoncoding RNAs (ncRNAs) defy the central dogma by representing a family of RNA molecules that are not translated into protein but can convey information encoded in their DNA. Elucidating the exact function of ncRNA has been a focus of discovery in the last decade and remains challenging. Nevertheless, the importance of understanding ncRNA is apparent since these molecules regulate gene expression at the transcriptional and post-transcriptional level exerting pleiotropic effects critical in development, oncogenesis, and immunity. NcRNAs have been referred to as “the dark matter of the nucleus”, and unraveling their role in physiologic and pathologic processes will provide vast opportunities for basic and translational research with the potential for significant therapeutic progress. Consequently, strong efforts are underway to exploit the therapeutic utility of ncRNA, some of which have been approved by the US Food and Drug Administration and the European Medicines Agency. The use of ncRNA therapeutics (or “vaccines” if defined as anti-disease agents) may result in improved curative strategies when used alone or in combination with existing treatments. This review will focus on the role of ncRNA therapeutics in prostatic carcinoma while exploring basic biological aspects of these molecules that represent about 97% of the transcriptome in humans.https://www.mdpi.com/2076-393X/10/2/276noncoding RNAncRNA therapeuticsncRNA “vaccines”prostatic carcinoma |
| spellingShingle | Victor E. Nava Pin-Yu Perera Nirbhay Kumar Maneesh Jain Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges Vaccines noncoding RNA ncRNA therapeutics ncRNA “vaccines” prostatic carcinoma |
| title | Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges |
| title_full | Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges |
| title_fullStr | Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges |
| title_full_unstemmed | Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges |
| title_short | Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges |
| title_sort | noncoding rna based therapeutics with an emphasis on prostatic carcinoma progress and challenges |
| topic | noncoding RNA ncRNA therapeutics ncRNA “vaccines” prostatic carcinoma |
| url | https://www.mdpi.com/2076-393X/10/2/276 |
| work_keys_str_mv | AT victorenava noncodingrnabasedtherapeuticswithanemphasisonprostaticcarcinomaprogressandchallenges AT pinyuperera noncodingrnabasedtherapeuticswithanemphasisonprostaticcarcinomaprogressandchallenges AT nirbhaykumar noncodingrnabasedtherapeuticswithanemphasisonprostaticcarcinomaprogressandchallenges AT maneeshjain noncodingrnabasedtherapeuticswithanemphasisonprostaticcarcinomaprogressandchallenges |